AC Immune S.A.
NASDAQ:ACIUBiotechnology
+$0.04 today
- Market cap
- $214.74M
- Beta
- 1.56
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$0.67
Volume 0.12M
Average 0.32M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
AC Immune S.A.
NASDAQ:ACIU
Intrinsic Alpha fair value
Locked
Current Price
$2.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -3.2% | +102.2% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -3.2% over three years. Forward estimates point to Revenue at +102.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Alpha Tau Medical Ltd. NASDAQ:DRTS | $1.24B | $13.38 | Not rated | -15.2 | +228.53% |
Alto Neuroscience, Inc. NYSE:ANRO | $1.18B | $29.54 | Not rated | -9.8 | +68.88% |
Silence Therapeutics plc NASDAQ:SLN | $936.65M | $19.83 | Not rated | -3.9 | +193.33% |
Annexon, Inc. NASDAQ:ANNX | $642.26M | $3.92 | Not rated | -4.8 | +8.44% |
Lyell Immunopharma, Inc. NASDAQ:LYEL | $351.57M | $14.30 | Not rated | -1.1 | -23.76% |
Contineum Therapeutics, Inc. Class A Common Stock NASDAQ:CTNM | $348.58M | $9.86 | Not rated | -7.5 | -17.03% |
Amarin Corporation plc NASDAQ:AMRN | $235.37M | $11.38 | Not rated | -9.9 | -32.56% |
Cellectis S.A. NASDAQ:CLLS | $118.86M | $1.18 | Not rated | -4.6 | -74.21% |
Mereo BioPharma Group plc NASDAQ:MREO | $49.10M | $0.31 | Not rated | -1.4 | -82.42% |
Aldeyra Therapeutics, Inc. NASDAQ:ALDX | $38.86M | $0.64 | Not rated | -4.2 | -81.67% |
Continue the stock analysis
Jump to another research area for this company.